DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
DURECT Co. (NASDAQ: DRRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.
DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.